Geneyx

Whole Genome Sequencing Variant Analysis and Interpretation for COVID 19 Patients. Do carriers of certain variants increase or decrease the expression levels, and in turn, contribute to the sensitivity or resistance to the virus? In the context of the novel coronavirus, SARS-Cov-2, variants that lead to susceptibility to or resistance to infection may prove to be useful to determine prognosis and triage of patients that are infected and might even be the target of tailored treatment.

production V-1 is ready, the Analysis module installed in more than 20 customers in 12 countries

In the throes of the COVID-19 outbreak, individuals and governments worldwide are turning to science for answers.
The last global outbreak to cause this much panic was the Spanish flu, which is estimated to have killed 50 million and infected 500 million people between 1918 and 1919. The cause of that disease was at the time unknown. By contrast, the viral agent of COVID-19 was discovered just weeks after the outbreak was first detected in China in December 2019. The genome sequence of the virus was made publicly available, allowing hundreds of projects to begin searching for a preventative vaccine. Potential curative drugs could also be considered based on the knowledge of viral structure that the genome sequence yielded and one, remdesivir, is showing promise in trials in China and the US.

Platforms for harmonizing and analyzing data as it is generated on patients in various locations and facilities together with consistent informed consent, IRB, and sample collection protocols.

The research - look for informative common polymorphisms, protective loss-of-function mutations, and other genetic factors that may coincide with individuals' propensity for SARS-CoV-2 infection or progression.

We propose to use Illumina based next-generation sequencing (NGS) to perform whole-genome sequencing on cases of individuals severely affected by the novel coronavirus SARS-CoV-2 causing COVID-19 disease and compare them to asymptomatic, mildly affected or moderately affected controls to discover risk and protective variants associated with this infectious disease that is rapidly spreading in the global population.

Centogene, CeGAt, Colors, Nebula genomics,

it is a technical advantage that creates business solution:
Geneyx is the only Genetic software suite that provides labs with ‘Dragen inside’ solution and with Weizmann institute's GeneCards Knowledgebase, plus unlimited secure storage and sharing option. the quality of the solution allows us to aggregate priceless genetic- clinical data sets, for the scientific, Pharma companies

1. A fully deployed platform, all 4 modules in full operating status:
a. Data b. Analysis c. Apps g. Research
2. 20 SaaS paid labs fully deployed our platform worldwide.
3. Pilot underway, in Europe, the US and China, and building local-based traction
4. 5OK Exome based complete cases and 10K Whole Genome complete cases in storage.
5. Pharma company customers

Geneyx offers the genetic lab, four modules, DATA- to collect the raw sequenced data directly from the sequencer, running customized pipe-line, or a “Dragen inside” proprietary seamless solution, The Geneyx Analysis- analyze and interpret, the sequenced genome, knowledge-based using “Gene-Cards”. Apps - Off the shelf’ CLIA/CAP – ready tests and reports. Research- Access to high quality, secured and diverse data with the freedom to operate and unlimited computation capabilities. Enabling worldwide research collaboration

1. A fully deployed platform, all 4 modules in full operating status:
a. Data b. Analysis c. Apps g. Research
2. 20 SaaS paid labs fully deployed our platform worldwide.
3. Pilot underway, in Europe, the US and China, and building local-based traction
4. 5OK Exome based complete cases and 10K Whole Genome complete cases in storage.
5. Pharma company customers

Equity

Regulations
GDPR/ HIPAA

We are participating in
https://gin-austria.com/programs/goAustria

We won 3 grants from Israel Innovation Authority
We Won pitch night by Next leap ventures

Raw genetic data anonymization encryption for HIPPA/GDPR complying storage.
TGex - The GeneCards Suite-powered end-to-end NGS analysis and interpretation platform
TOVANA Health (partner) - Whole Exome / Whole-genome CLIA/CAP approved tests and clinical reporting product (DNA UNLOCK)